SYK

AI Memo

Stryker

As of 2026-09-03/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 2026 results and FY2026 outlook • 2026-07-30

Base target: $335 / p=55% prob

Biggest risk

The thesis depends on continued procedure volumes and clean cyber recovery. Acquisition closing, integration, and commercial uptake remain uncertain; recent insider open-market sales add sentiment caution but are not operating evidence. [#SEC-FORM4-2026-08-26] [#SEC-FORM4-2026-08-20]

Invalidation

Break below $275 or thesis failure.

What would change my mind?

Strong Q2 organic growth, unit-volume contribution, margin expansion, and narrowed guidance support a constructive operating thesis. ZuriMED adds a shoulder-technology option, though its financial impact is not yet established. [#SEC-8K-2026-07-30] [#IR-2026-08-31]

Research note

Recommendation

—

Confidence

high

As of

2026-09-03

Base target

$335

p=55%

Bull target

$390

p=25%

Bear target

$275

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cyber-incident recovery and execution risk
Sustained procedure-volume and innovation execution
Strong Q2 organic growth, unit-volume contribution, margin expansion, and narrowed guidance support a constructive operating thesis.

BearKey bullets

Analyst consensus count, target revisions, and post-earnings estimate changes are unavailable.
FY2026 guidance assumes modestly positive pricing and slightly favorable foreign exchange.
Further cyber-incident recovery problems could disrupt operations or customer service.

WatchKey bullets

Q2 2026 results and FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $335 (p=55%)

Target spread vs base: +16% / -18%

Scenario probabilities

Bull Target: $390 (p=25%)Base Target: $335 (p=55%)Bear Target: $275 (p=20%)

Commentary

Primary-source operating evidence is strong and positive, but forward visibility is only moderate because analyst revisions and market-reaction attribution are unavailable. Recent company news is constructive around ZuriMED, while insider sales warrant monitoring. No social-context coverage was supplied; social and options fields are therefore not decision-useful.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cyber-incident recovery and execution risk
Sustained procedure-volume and innovation execution

Scenarios

Bull Target (Scenario probability)

$390 / p=25% prob

Base Target (Scenario probability)

$335 / p=55% prob

Bear Target (Scenario probability)

$275 / p=20% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-30
Q2 2026 results and FY2026 outlook
Stryker reported 9.4% sales growth, 9.0% organic growth, 17.9% adjusted EPS growth, and narrowed FY2026 guidance to 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS. Management cited cyber-incident recovery and regained momentum entering the second half. [#SEC-8K-2026-07-30]
Prob 100.00% • Move 3.50% • Priced-in 90.00%
EVENT2026-08-31
ZuriMED acquisition expands shoulder portfolio
Stryker announced a definitive agreement to acquire ZuriMED and its commercialized FiberLocker rotator-cuff augmentation technology. Closing remains subject to customary conditions, so near-term financial contribution is unproven. [#IR-2026-08-31]
Prob 80.00% • Move 2.50% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Cyber-incident recovery and execution risk
2026-09-30
Management reported significant progress recovering from the cyber incident, but further operational disruption or slower normalization remains a near-term downside risk. [#SEC-8K-2026-07-30]
Prob 32% • Move -6% • Priced-in 60%

Long-term Catalysts

Months to a year

Sustained procedure-volume and innovation execution
2026-12-31
The Q2 filing attributes organic growth primarily to increased unit volume across MedSurg/Neurotechnology and Orthopaedics, while management expects continued innovation and disciplined execution to support high-end MedTech growth. [#SEC-8K-2026-07-30]
Prob 68% • Move 10% • Priced-in 55%

Risks

Analyst consensus count, target revisions, and post-earnings estimate changes are unavailable.
FY2026 guidance assumes modestly positive pricing and slightly favorable foreign exchange.
Further cyber-incident recovery problems could disrupt operations or customer service.
Recent Form 4 records show substantial open-market sales by a director and an officer. [#SEC-FORM4-2026-08-20] [#SEC-FORM4-2026-08-26]
ZuriMED closing, integration, adoption, and financial contribution are not yet demonstrated.

Peers

Symbol	Summary
BSX	Direct medical-device peer for growth and valuation comparison; packet provides no comparative estimates.
EW	Relevant cardiovascular medical-device peer; useful for sector-relative valuation, with no peer metrics supplied.
ISRG	Direct surgical-technology peer and relevant innovation comparator; no packet-specific revision data available.
ABT	Large diversified healthcare-device comparator, but less focused than the direct medtech peers above.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

BSX

Direct medical-device peer for growth and valuation comparison; packet provides no comparative estimates.

Relevant cardiovascular medical-device peer; useful for sector-relative valuation, with no peer metrics supplied.

ISRG

Direct surgical-technology peer and relevant innovation comparator; no packet-specific revision data available.

ABT

Large diversified healthcare-device comparator, but less focused than the direct medtech peers above.